Search research articles
Contact Us
Filters
Showing results (41-50 of 68) with videos related to
Page
of 7
Sort By:
Current Opinion in Supportive and Palliative Care
|
September 29, 2017
Research priorities in cancer cachexia: The University of Rochester Cancer Center NCI Community Oncology Research Program Research Base Symposium on Cancer Cachexia and Sarcopenia
Richard F Dunne, Karen M Mustian, Jose M Garcia, et al.
Journal of Clinical Medicine
|
May 13, 2026
Total Neoadjuvant Therapy with FOLFOX Followed by Short-Course Radiation in Locally Advanced Rectal Cancer-An Alternative Approach Evaluated in a Single-Center Clinical Trial
Janice Zhao, Andrea M Baran, Larissa K F Temple, et al.
Cell Reports
|
August 31, 2022
Arid1a mutation suppresses TGF-β signaling and induces cholangiocarcinoma
Bing Guo, Scott C Friedland, William Alexander, et al.
Journal of Gastrointestinal Oncology
|
August 29, 2018
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
David A Fabrizio, Thomas J George, Richard F Dunne, et al.
Cancer Chemotherapy and Pharmacology
|
October 15, 2013
Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma
Lipika Goyal, Jeffrey G Supko, Jordan Berlin, et al.
Disease Models & Mechanisms
|
February 28, 2024
Smad4 restricts injury-provoked biliary proliferation and carcinogenesis
William B Alexander, Wenjia Wang, Margaret A Hill, et al.
The Oncologist
|
December 20, 2011
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping
Darrell R Borger, Kenneth K Tanabe, Kenneth C Fan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2015
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer
Alex A Adjei, Donald A Richards, Anthony El-Khoueiry, et al.
Journal of Hepatology
|
April 22, 2021
FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted
Adrián Vallejo, Oihane Erice, Rodrigo Entrialgo-Cadierno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study
Andrew X Zhu, Dushyant V Sahani, Dan G Duda, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 68) with videos related to
Sort By:
Page
of 7
Current Opinion in Supportive and Palliative Care
|
September 29, 2017
Research priorities in cancer cachexia: The University of Rochester Cancer Center NCI Community Oncology Research Program Research Base Symposium on Cancer Cachexia and Sarcopenia
Richard F Dunne, Karen M Mustian, Jose M Garcia, et al.
Journal of Clinical Medicine
|
May 13, 2026
Total Neoadjuvant Therapy with FOLFOX Followed by Short-Course Radiation in Locally Advanced Rectal Cancer-An Alternative Approach Evaluated in a Single-Center Clinical Trial
Janice Zhao, Andrea M Baran, Larissa K F Temple, et al.
Cell Reports
|
August 31, 2022
Arid1a mutation suppresses TGF-β signaling and induces cholangiocarcinoma
Bing Guo, Scott C Friedland, William Alexander, et al.
Journal of Gastrointestinal Oncology
|
August 29, 2018
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
David A Fabrizio, Thomas J George, Richard F Dunne, et al.
Cancer Chemotherapy and Pharmacology
|
October 15, 2013
Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma
Lipika Goyal, Jeffrey G Supko, Jordan Berlin, et al.
Disease Models & Mechanisms
|
February 28, 2024
Smad4 restricts injury-provoked biliary proliferation and carcinogenesis
William B Alexander, Wenjia Wang, Margaret A Hill, et al.
The Oncologist
|
December 20, 2011
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping
Darrell R Borger, Kenneth K Tanabe, Kenneth C Fan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2015
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer
Alex A Adjei, Donald A Richards, Anthony El-Khoueiry, et al.
Journal of Hepatology
|
April 22, 2021
FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted
Adrián Vallejo, Oihane Erice, Rodrigo Entrialgo-Cadierno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study
Andrew X Zhu, Dushyant V Sahani, Dan G Duda, et al.
Page
of 7